Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          

LT3001

LT3001

A new chemical entity (NCE) intended for the treatment of acute ischemic stroke in patients who are not eligible (qualified) for current standard therapy, tissue plasminogen activator (tPA).

Request for Collaboration
Overview
LT3001 contains a new chemical entity which is composed of a thrombolytic polypeptide and a small molecule moiety with anti-oxidation activity. In rodent disease models where LT3001 was administered outside of the “golden (3) hours” post- stroke when tPA cannot be used, it significantly reduced brain infarction, restored blood flow and improved neuronal behavior score without hemorrhage. LT3001 holds promise as a safer and efficacious therapy for the treatment of acute ischemic stroke by combining the thrombolysis and neuroprotection in one treatment. IND applications in the US and Taiwan is planned in 2016.
Application
Issues with Current Therapy
The only FDA approved drug treatment for ischemic strokes is tPA. Although tPA is now an established stroke treatment, its use is very limited (3-5% of stroke patients). In addition to its many contraindication, tPA can only be administered to those patients within 3 hours of ischemic stroke onset, and is associated with significant risks of hemorrhage and neurotoxicity

Differentiating Characteristics
Preclinical data in vitro and in multiple animal stroke models have shown:
-Efficacy up to 24 hours post-stroke
-Blood clots dissolved without observation of hemorrhage
-Superior safety profile with no sign of hemorrhage even after repeated dose
-Neuroprotection – protect brain from endothelial cell damage and reperfusion injury
Patent Portfolio
Patents for the composition and method of use were filed in 18 countries/regions worldwide that encompass medically advanced countries and emerging markets.
Collaboration Options
Actively seeking licensees for tech-transfer agreements worldwide.
People who like this also like
  • cGMP Complied Pilot FacilitycGMP Complied Pilot Facility
  • TRIA11TRIA11
  • Analytical capabilityAnalytical capability
  • Newborn genetic screening for hearing impairment using real-time PCR with FRET probesNewborn genetic screening for hearing impairment using real-time PCR with FRET probes
  • HPAPI manufacturingHPAPI manufacturing
  • Candidate selectionCandidate selection
  • FB704AFB704A
  • OB318- New drug for anti-liver cancerOB318- New drug for anti-liver cancer
  • Six Genomic Technology PlatformsSix Genomic Technology Platforms
  • CHAP™CHAP™